Please assess the completion status of the following clinical trial:

Trial Title: Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Fibrolamellar hepatocellular carcinoma histopathologically proven~* Inoperable/advanced (Tumor recurrence inoperable or metastatic with no surgical indication).~* Available Tumor tissue for analysis(biopsy or surgical specimen)~* Performance status WHO ≤ 2.~* Adequate organ function :~  * Hematology (absolute neutrophil count equal or superior to 1,5 x 10\*9/l , platelet equal or superior to 100 x 10\*9/l),~ * clearance of creatinine \> 60 ml/min),~ * AST/ALT ≤ 5 N, PAL ≤ 5 N, total bilirubin ≤ 2N.~Exclusion Criteria:~* Hypersensitivity to sunitinib.~* Contraindication to sunitinib, including uncontrolled hypertension, medical history of cerebrovascular accident, unstable cardiac pathology despite optimal medical therapy (myocardial infarction within the 6 months prior to study drug administration, severe/unstable angina ), active hemorrhagic syndrome or concomitant treatment with anticoagulants.~* Any severe acute or chronic co-morbid that may compromise to comply with study participation : uncontrolled infection, symptomatic congestive heart failure, liver disturbance, chronic renal failure, active gastro-duodenal ulcer (nonexhaustive list)~* Known brain metastases.~* Diagnosis of any second malignancy within the last 3 years, except for basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri~* Current treatment on another clinical trial.~* Prior treatment with an investigational agent within 4 weeks~* Patient on i.v bisphosphonate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient treated (Type: EXPERIMENTAL): patient who receive sunitinib

Based on this trial design, predict the completion outcome and termination type (if applicable).